CCA
SRPT icon

Catalyst Capital Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Catalyst Capital Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-18,500
Closed -$2.44M – 529
2018
Q2 		$2.44M Buy
+18,500
New +$1.74M 0.09% 122
2013
Q4 		– Sell
-36,050
Closed -$1.7M – 312
2013
Q3 		$1.7M Buy
+36,050
New +$1.39M 0.93% 8

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Catalyst Capital Advisors's SRPT Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2018, closing a stake of 18,500 shares — an estimated $2.44M sold.

Catalyst Capital Advisors first reported a position in SRPT in Q3 2013 and held it in 2 quarters. The position peaked at $2.44M in Q2 2018. 344 funds tracked by Wall St. Rank hold SRPT as of Q3 2018.

  • Catalyst Capital Advisors reported no remaining Sarepta Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 18,500 Sarepta Therapeutics shares in Q3 2018, an estimated $2.44M.
  • Catalyst Capital Advisors first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 2 quarters.
  • Catalyst Capital Advisors's Sarepta Therapeutics position peaked at $2.44M in Q2 2018.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.